Cancer-Specific Mortality in Asian American Women Diagnosed with Gynecologic Cancer: A Nationwide Population-Based Analysis.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
09
07
2021
revised:
07
10
2021
accepted:
10
12
2021
pubmed:
23
12
2021
medline:
3
5
2022
entrez:
22
12
2021
Statut:
ppublish
Résumé
Cancer is the leading cause of death in Asian Americans (AA), the fastest-growing U.S. population group. Despite heterogeneity in socioeconomic status and health behaviors by ethnicity, few studies have assessed cancer outcomes across AA ethnic groups. We examined differences in gynecologic cancer mortality between AA ethnic groups and non-Hispanic Whites (NHW). Using the Surveillance, Epidemiology, and End Results database, we identified ovarian (n = 69,113), uterine (n = 157,340), and cervical cancer cases (n = 41,460) diagnosed from 1991-2016. Competing risk regression was used to compare cancer-specific mortality for AAs by ethnicity, using NHW as the reference population. In adjusted analyses, AAs had a lower risk of ovarian [HR, 0.90; 95% confidence interval (CI), 0.86-0.94] and cervical cancer death (HR, 0.80; 95% CI, 0.75-0.87) than NHWs, with stronger associations among those ≥50 years at diagnosis [(HRovary, 0.87; 95% CI, 0.82-0.92); (HRcervix, 0.74; 95% CI, 0.67-0.81)]. No overall difference was noted for uterine cancer death (HR, 1.03; 95% CI, 0.97-1.10); however, AAs <50 years at diagnosis had a higher risk of uterine cancer death than NHWs (HR, 1.26; 95% CI, 1.08-1.46). Patterns of cancer mortality were heterogeneous, with Filipino and Chinese women at the highest risk of uterine cancer death and Indian/Pakistani women at the lowest risk of ovarian and cervical cancer death. There are significant differences in gynecologic cancer mortality between AAs and NHWs, with heterogeneity by AA ethnicity. Disaggregated analysis of AA is needed to better understand the burden of gynecologic cancer and identify high-risk groups for cancer prevention efforts.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer is the leading cause of death in Asian Americans (AA), the fastest-growing U.S. population group. Despite heterogeneity in socioeconomic status and health behaviors by ethnicity, few studies have assessed cancer outcomes across AA ethnic groups. We examined differences in gynecologic cancer mortality between AA ethnic groups and non-Hispanic Whites (NHW).
METHODS
METHODS
Using the Surveillance, Epidemiology, and End Results database, we identified ovarian (n = 69,113), uterine (n = 157,340), and cervical cancer cases (n = 41,460) diagnosed from 1991-2016. Competing risk regression was used to compare cancer-specific mortality for AAs by ethnicity, using NHW as the reference population.
RESULTS
RESULTS
In adjusted analyses, AAs had a lower risk of ovarian [HR, 0.90; 95% confidence interval (CI), 0.86-0.94] and cervical cancer death (HR, 0.80; 95% CI, 0.75-0.87) than NHWs, with stronger associations among those ≥50 years at diagnosis [(HRovary, 0.87; 95% CI, 0.82-0.92); (HRcervix, 0.74; 95% CI, 0.67-0.81)]. No overall difference was noted for uterine cancer death (HR, 1.03; 95% CI, 0.97-1.10); however, AAs <50 years at diagnosis had a higher risk of uterine cancer death than NHWs (HR, 1.26; 95% CI, 1.08-1.46). Patterns of cancer mortality were heterogeneous, with Filipino and Chinese women at the highest risk of uterine cancer death and Indian/Pakistani women at the lowest risk of ovarian and cervical cancer death.
CONCLUSIONS
CONCLUSIONS
There are significant differences in gynecologic cancer mortality between AAs and NHWs, with heterogeneity by AA ethnicity.
IMPACT
CONCLUSIONS
Disaggregated analysis of AA is needed to better understand the burden of gynecologic cancer and identify high-risk groups for cancer prevention efforts.
Identifiants
pubmed: 34933960
pii: 1055-9965.EPI-21-0829
doi: 10.1158/1055-9965.EPI-21-0829
pmc: PMC8901555
mid: NIHMS1766177
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
578-587Subventions
Organisme : NCI NIH HHS
ID : T32 CA094061
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Gynecol Oncol. 2014 May;133(2):353-61
pubmed: 24406291
Int J Gynecol Cancer. 2019 Oct;29(8):1244-1251
pubmed: 31422351
J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49
pubmed: 23138163
Br J Cancer. 2014 Aug 26;111(5):1014-20
pubmed: 24983370
Med Care. 2016 Sep;54(9):e55-64
pubmed: 24638121
Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):167-72
pubmed: 19469648
Clin Cancer Res. 2016 Dec 1;22(23):5909-5914
pubmed: 27521449
Cancer. 2004 Sep 1;101(5):1051-7
pubmed: 15329915
Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):58-65
pubmed: 34697057
Ethn Dis. 2001 Fall;11(4):598-605
pubmed: 11763284
CA Cancer J Clin. 2007 Jul-Aug;57(4):190-205
pubmed: 17626117
JAMA Intern Med. 2018 Sep 1;178(9):1210-1222
pubmed: 30083701
BJOG. 2019 Aug;126(9):1104-1115
pubmed: 30908874
JAMA. 2019 Dec 24;322(24):2389-2398
pubmed: 31860047
Clin Genet. 2011 Jul;80(1):89-92
pubmed: 20950396
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1968-73
pubmed: 18708386
Gynecol Oncol. 2019 Aug;154(2):420-425
pubmed: 31229298
Cancer Causes Control. 2009 Sep;20(7):1139-50
pubmed: 19288217
Cancer Causes Control. 2004 Apr;15(3):243-53
pubmed: 15090719
J Natl Cancer Inst. 2007 Sep 19;99(18):1384-94
pubmed: 17848670
Mod Pathol. 2000 Mar;13(3):295-308
pubmed: 10757340
J Cancer Educ. 2011 Dec;26(4):740-6
pubmed: 21553330
Endocr Relat Cancer. 2000 Dec;7(4):227-42
pubmed: 11174845
Int J Gynecol Cancer. 2017 Oct;27(8):1650-1657
pubmed: 28692638
Gynecol Oncol. 2013 May;129(2):277-84
pubmed: 23485770
Gynecol Oncol. 2015 Mar;136(3):491-7
pubmed: 25455734
Am Soc Clin Oncol Educ Book. 2015;:114-21
pubmed: 25993149
Am J Obstet Gynecol. 2019 Oct;221(4):318.e1-318.e9
pubmed: 31125544
Cancer Prev Res (Phila). 2014 Jan;7(1):42-53
pubmed: 24403289
Am J Epidemiol. 2009 Jul 15;170(2):244-56
pubmed: 19494242
Cancer Causes Control. 2006 Aug;17(6):771-81
pubmed: 16783605
Diabetes Care. 2009 Sep;32(9):1644-6
pubmed: 19509010
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Diabetes Complications. 2013 Sep-Oct;27(5):429-35
pubmed: 23743139
J Assist Reprod Genet. 2017 Jun;34(6):765-774
pubmed: 28417349
J Natl Cancer Inst. 2019 Jan 1;111(1):60-68
pubmed: 29718305
JAMA. 2008 Dec 17;300(23):2754-64
pubmed: 19088353
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
Br J Cancer. 2013 Apr 16;108(7):1508-14
pubmed: 23470470
Cancer Genet. 2014 Apr;207(4):160-3
pubmed: 24853100
Cancer Causes Control. 2007 Mar;18(2):177-87
pubmed: 17219013
J Cancer Epidemiol. 2011;2011:107497
pubmed: 22496688
Obstet Gynecol. 2015 Sep;126(3):491-497
pubmed: 26244529
Gynecol Oncol. 2018 Feb;148(2):275-280
pubmed: 29195926
Cancer Causes Control. 2001 Oct;12(8):703-11
pubmed: 11562110
J Natl Cancer Inst. 2004 Nov 17;96(22):1659-68
pubmed: 15547178
Cancer. 2003 May 1;97(9):2196-202
pubmed: 12712471
J Natl Cancer Inst. 2015 Mar 20;107(6):djv054
pubmed: 25794888
Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):243-57
pubmed: 19331590